Molecular testing for thyroid nodules: the experience at McGill University teaching hospitals in Canada
M Rajab, RJ Payne, VI Forest, M Pusztaszeri - Cancers, 2022 - mdpi.com
Simple Summary The aim of this review is to provide a general overview about the
molecular markers (mutations and alterations) of thyroid cancers, present several molecular …
molecular markers (mutations and alterations) of thyroid cancers, present several molecular …
Role of miR‑181a‑5p in cancer
MicroRNAs (miRNAs) are non‑coding RNAs (ncRNAs) that can post‑transcriptionally
suppress targeted genes. Dysregulated miRNAs are associated with a variety of diseases …
suppress targeted genes. Dysregulated miRNAs are associated with a variety of diseases …
OGT regulated O-GlcNAcylation promotes papillary thyroid cancer malignancy via activating YAP
X Li, Z Wu, J He, Y Jin, C Chu, Y Cao, F Gu, H Wang… - Oncogene, 2021 - nature.com
The incidence of thyroid cancer is growing rapidly during the past decades worldwide.
Although most thyroid tumors are curable, some patients diagnosed with distant metastases …
Although most thyroid tumors are curable, some patients diagnosed with distant metastases …
The relationship between thyrotropin serum concentrations and thyroid carcinoma
X Zhang, L Tian, D Teng, W Teng - Cancers, 2023 - mdpi.com
Simple Summary Thyroid-stimulating hormone (TSH) plays a role in the regulation of thyroid
hormones and is an important indicator for assessing thyroid function. Thyroid cancer (TC) is …
hormones and is an important indicator for assessing thyroid function. Thyroid cancer (TC) is …
Aggressive variants of follicular cell-derived thyroid carcinoma: an overview
Purpose The incidence of thyroid carcinoma has increased globally in the past years.
Papillary thyroid carcinoma (PTC) is the most frequent neoplasm of the thyroid gland …
Papillary thyroid carcinoma (PTC) is the most frequent neoplasm of the thyroid gland …
[HTML][HTML] Papillary thyroid carcinoma
F Limaiem, A Rehman, C Anastasopoulou, T Mazzoni - 2019 - europepmc.org
Papillary Thyroid Carcinoma - Abstract - Europe PMC Sign in | Create an account https://orcid.org
Europe PMC Menu About Tools Developers Help Contact us Helpdesk Feedback Twitter Blog …
Europe PMC Menu About Tools Developers Help Contact us Helpdesk Feedback Twitter Blog …
Identification and validation of a prognostic signature for thyroid cancer based on ferroptosis-related genes
Y Wang, J Yang, S Chen, W Wang, L Teng - Genes, 2022 - mdpi.com
Background: Thyroid cancer is the most common endocrine malignancy. Most PTC patients
have a good prognosis; however, there are 5–20% of PTC patients with extra-thyroidal …
have a good prognosis; however, there are 5–20% of PTC patients with extra-thyroidal …
Aggressive subtypes of papillary thyroid carcinoma smaller than 1 cm
JS Lee, JS Lee, HJ Yun, SM Kim… - The Journal of …, 2023 - academic.oup.com
Context Tumor size is important in determining the range of surgery in papillary thyroid
carcinomas (PTCs), especially those smaller than 1 cm. Objective We aimed to analyze the …
carcinomas (PTCs), especially those smaller than 1 cm. Objective We aimed to analyze the …
Molecular Pathology of Non-familial Follicular Epithelial–Derived Thyroid Cancer in Adults: From RAS/BRAF-like Tumor Designations to Molecular Risk Stratification
This review addresses the impact of molecular alterations on the diagnosis and prognosis of
differentiated thyroid carcinoma (DTC), including papillary, follicular, and well-differentiated …
differentiated thyroid carcinoma (DTC), including papillary, follicular, and well-differentiated …
TERT promoter and BRAF V600E mutations in papillary thyroid cancer: a single-institution experience in Korea
MJ Kim, JK Kim, GJ Kim, SW Kang, J Lee, JJ Jeong… - Cancers, 2022 - mdpi.com
Simple Summary TERT promoter mutation has recently emerged as a promising prognostic
biomarker for aggressive papillary thyroid cancer (PTC), along with BRAF B600E mutation …
biomarker for aggressive papillary thyroid cancer (PTC), along with BRAF B600E mutation …